Progress in the study of some important natural bioactive cyclopeptides

Yaoxue Xuebao

Volumn 47, Issue 3, 2012, Pages 271-279

  Xu, Wen Yan ^a   Zhao, Si Meng ^a,b   Zeng, Guang Zhi ^a   He, Wen Jun ^a   Xu, Hui Min ^a,b   Tan, Ning Hua ^a  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Anti tumor; Antibiotics; Immunosuppressive; Mechanism; Natural active cyclopeptides

Indexed keywords

ASTIN C; CYCLOPEPTIDE; CYCLOSPORIN A; DAPTOMYCIN; DEHYDRODIDEMNIN B; GRAMICIDIN S; UNCLASSIFIED DRUG; VANCOMYCIN;

DRUG ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CYCLOSPORINE; DAPTOMYCIN; DEPSIPEPTIDES; GRAMICIDIN; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR STRUCTURE; NEOPLASMS; PEPTIDES, CYCLIC; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; VANCOMYCIN;

EID: 84860877856     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Ruegger A, Kuhn M, Lichti H, et al. Cyclosproin-A, a peptide metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity [J]. Helv Chim Acta, 1976, 59: 1075-1092.
2. Wikipedia contributors. Tolypocladium inflatum [DB/OL]. Wikipedia, The Free Encyclopedia 2011 [2011-11-07]. http://en.wikipedia.org/w/index.php?title= Tolypocladium-inflatum&oldid=434683065
3. Petcher TJ, Weber HP, Ruegger A. Crystal and molecular-structure of an iodo-derivative of cyclic undecapeptide cyclosporin-A [J]. Helv Chim Acta, 1976, 59: 1480-1489.
4. Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin-A: a new antilymphocytic agent [J]. Agents Actions, 1994, 43: 179-186.
5. Calne R. Cyclosporin as a milestone in immunosuppression [J]. Transplant Proc, 2004, 36: S13-S15.
6. Matsuda S, Koyasu S. Mechanisms of action of cyclosporin [J]. Immunopharmacology, 2000, 47: 119-125.
7. Kronke M, Leonard WJ, Depper JM, et al. Cyclosproin-A inhibits T-cell growth-factor gene-expression at the level of messenger-RNA transcription [J]. Proc Natl Acad Sci USA, 1984, 81: 5214-5218. (Pubitemid 14011293)
8. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes [J]. Cell, 1991, 66: 807-815. (Pubitemid 121001714)
9. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward [J]. Immunopharmacology, 2000, 47: 63-83. (Pubitemid 30394533)
10. Xu Q, Sun Y. Novel immunosuppression stemming from the selective activity of Chinese herbal drugs [J]. Prog Chem, 2009, 21: 55-62.
11. Ryffel B, Mihatsch MJ. Cyclosporin nephrotoxicity [J]. Toxicol Pathol, 1986, 14: 73-82.
12. Aebi JD, Deyo DT, Sun CQ, et al. Synthesis, conformation, and immunosuppressive activities of three analogs of cyclosporin A modified in the 1-position [J]. J Med Chem, 1990, 33: 999-1009. (Pubitemid 20085905)
13. Anglade E, Aspeslet LJ, Weiss SL. A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin [J]. Clin Ophthalmol (Auckland, N.Z.), 2008, 2: 693-702.
14. Hancock REW, Chapple DS. Peptide antibiotics [J]. Antimicrob Agents Chemoth, 1999, 43: 1317-1323. (Pubitemid 29259318)
15. Wikipedia contributors. Gramidin S [DB/OL]. Wikipedia, The Free Encyclopedia 2011 [2011-11-07]. http://en.wikipedia.org/w/index.php?title= Gramicidin-S&oldid=454903025
16. Gause GF, Brazhnokova MG. Gramicidin S and its use in the treatment of infected wounds [J]. Nature, 1944, 154: 703.
17. Hull SE, Karlsson R, Main P, et al. The crystal structure of a hydrated gramicidin S-urea complex [J]. Nature, 1978, 275: 206-207. (Pubitemid 9008028)
18. Conti E, Stachelhaus T, Marahiel MA, et al. Structural basis for the activation of phenylalanine in the non-ribosomal biosynthesis of gramicidin S [J]. EMBO J, 1997, 16: 4174-4183. (Pubitemid 27298170)
19. Polin AN, Egorov NS. Structural and functional peculiarities of gramicidin S in connection with its antibiotic activity [J]. Antibiotiki Khimioter, 2003, 48: 29-32.
20. Mogi T, Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics [J]. Cell Mol Life Sci, 2009, 66: 3821-3826.
21. Andersen OS, Koeppe RE, Roux B. Gramicidin channels [J]. IEEE Trans Nanobioscience, 2005, 4: 10-20.
22. Prenner EJ, Kiricsi M, Jelokhani-Niaraki M, et al. Structure-activity relationships of diastereomeric lysine ring size analogs of the antimicrobial peptide gramicidin S [J]. J Biol Chem, 2005, 280: 2002-2011.
23. Prenner EJ, Lewis R, McElhaney RN. The interaction of the antimicrobial peptide gramicidin S with lipid bilayer model and biological membranes [J]. Biochim Biophys Acta, 1999, 1462: 201-221.
24. Burkhart BM, Gassman RM, Langs DA, et al. Gramicidin D conformation, dynamics and membrane ion transport [J]. Pept Sci, 1999, 51: 129-144. (Pubitemid 29352516)
25. Levine DP. Vancomycin: a history [J]. Clin Infect Dis, 2006, 42: S5-S12. (Pubitemid 41832060)
26. Wikipedia contributors. Vancomycin [DB/OL]. Wikipedia, The Free Encyclopedia 2011 [2011-11-07]. http://en.wikipedia.org/wiki/Vancomycin
27. Schafer M, Schneider TR, Sheldrick GM. Crystal structure of vancomycin [J]. Structure, 1996, 4: 1509-1515. (Pubitemid 27050282)
28. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics [J]. Eur J Clin Microbiol Infect Dis, 1989, 8: 943-950. (Pubitemid 20006106)
29. Lehmann C, Bunkoczi G, Vertesy L, et al. Structures of glycopeptide antibiotics with peptides that model bacterial cell-wall precursors [J]. J Mol Biol, 2002, 318: 723-732. (Pubitemid 34729364)
30. Loll PJ, Derhovanessian A, Shapovalov MV, et al. Vancomycin forms ligand-mediated supramolecular complexes [J]. J Mol Biol, 2009, 385: 200-211.
31. Nitanai Y, Kikuchi T, Kakoi K, et al. Crystal structures of the complexes between vancomycin and cell-wall precursor analogs [J]. J Mol Biol, 2009, 385: 1422-1432.
32. Swenson J, Facklam R, Thornsberry C. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus and Lactobacillus species [J]. Antimicrob Agents Chemother, 1990, 34: 543-549. (Pubitemid 20122280)
33. Kuzin AP, Sun T, Jorczak-Baillass J, et al. Enzymes of vancomycin resistance: the structure of D-alanine-D-lactate ligase of naturally resistant Leuconostoc mesenteroides [J]. Structure, 2000, 8: 463-470. (Pubitemid 30304544)
34. Leung SSF, Tirado-Rives J, Jorgensen WL. Vancomycin analogs: seeking improved binding of D-Ala-D-Ala and D-Ala-D-Lac peptides by side-chain and backbone modifications [J]. Bioorg Med Chem, 2009, 17: 5874-5886.
35. Leung SSF, Tirado-Rives J, Jorgensen WL. Vancomycin resistance: modeling backbone variants with D-Ala-D-Ala and D-Ala-D-Lac peptides [J]. Bioorg Med Chem Lett, 2009, 19: 1236-1239.
36. Baltz RH, Miao V, Wrigley SK. Natural products to drugs: daptomycin and related lipopeptide antibiotics [J]. Nat Prod Rep, 2005, 22: 717-741. (Pubitemid 41830839)
37. Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections [J]. J Antimicrob Chemother, 2000, 46: 523-526.
38. Steenbergen JN, Alder J, Thorne GM, et al. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections [J]. J Antimicrob Chemother, 2005, 55: 283-288. (Pubitemid 40425449)
39. Schmitz FJ, Yasumoto T. The 1990 United States-Japan seminar on bioorganic marine chemistry, meeting report [J]. J Nat Prod, 1991, 54: 1469-1490.
40. Rinehart KL, Gloer JB, Hughes RG, et al. Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate [J]. Science, 1981, 212: 933-935. (Pubitemid 11120478)
41. Urdiales JL, Morata P, De Castro IN, et al. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates [J]. Cancer Lett, 1996, 102: 31-37.
42. Gomez-Fabre PM, de Pedro E, Medina MA, et al. Polyamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B [J]. Cancer Lett, 1997, 113: 141-144. (Pubitemid 27113240)
43. Beidler DR, Ahuja D, Wicha MS, et al. Inhibition of protein synthesis by didemnin B is not sufficient to induce apoptosis in human mammary carcinoma (MCF7) cells [J]. Biochem Pharmacol, 1999, 58: 1067-1074. (Pubitemid 29361473)
44. Broggini M, Marchini SV, Galliera E, et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4 [J]. Leukemia, 2003, 17: 52-59. (Pubitemid 36175888)
45. Cuadrado A, Garcia-Fernandez LF, Gonzalez L, et al. Aplidin™ induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK [J]. J Biol Chem, 2003, 278: 241-250. (Pubitemid 36043568)
46. Garcia-Fernandez LF, Cuadrado A, Alcaide V, et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta [J]. Oncogene, 2002, 21: 7533-7544. (Pubitemid 35305581)
47. Taraboletti G, Poli M, Dossi R, et al. Antiangiogenic activity of aplidine, a new agent of marine origin [J]. Br J Cancer, 2004, 90: 2418-2424. (Pubitemid 38961909)
48. Taddei ML, Chiarugi P, Cuevas C, et al. Oxidation and inactivation of low molecular weight protein tyrosine phosphatase by the anticancer drug aplidin [J]. Int J Cancer, 2006, 118: 2082-2088.
49. Gonzalez-Santiago L, Suarez Y, Zarich N, et al. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation [J]. Cell Death Differ, 2006, 13: 1968-1981. (Pubitemid 44542409)
50. Suarez Y, Gonzalez-Santiago L, Zarich N, et al. Plitidepsin cellular binding and Rac1/JNK pathway activation depend on membrane cholesterol content [J]. Mol Pharmacol, 2006, 70: 1654-1663.
51. Moneo V, Serelde BG, Leal JFM, et al. Levels of p27kip1 determine aplidin (plitidepsin) sensitivity [J]. Mol Cancer Ther, 2007, 6: 1310-1316. (Pubitemid 46711994)
52. Jou G, Gonzalez I, Albericio F, et al. Total synthesis of dehydrodidemnin B. Use of uronium and phosphonium salt coupling reagents in peptide synthesis in solution [J]. J Org Chem, 1997, 62: 354-366. (Pubitemid 27089012)
53. Rodriguez I, Polanco C, Cuevas F, et al. Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them: US, 7678765 [P]. 2010-03-16.
54. Tan NH, Zhou J. Plant cyclopeptides [J]. Chem Rev, 2006, 106: 840-895.
55. Jolad SD, Hoffman JJ, Torrance SJ, et al. Bouvardin and deoxybouvardin, antitumor cyclic hexapeptides from Bouvardia ternifolia (Rubiaceae) [J]. J Am Chem Soc, 1977, 99: 8040-8044. (Pubitemid 8236779)
56. Itokawa H, Takeya K, Mihara K, et al. Studies on the antitumor cyclic hexapeptides obtained from Rubiae radix [J]. Chem Pharm Bull, 1983, 31: 1424-1427. (Pubitemid 13061531)
57. Itokawa H, Takeya K, Mori N, et al. Studies on antitumor cyclic hexapeptides RA obtained from Rubiae radix, Rubiaceae. VI.: minor antitumor constituents [J]. Chem Pharm Bull, 1986, 34: 3762-3768. (Pubitemid 17192766)
58. Morita H, Yamamiya T, Takeya K, et al. New antitumor bicyclic hexapeptides, RA-XI, RA-XII, RA-XIII and RA-XIV from Rubia cordifolia [J]. Chem Pharm Bull, 1992, 40: 1352-1354.
59. Zou C, Hao XJ, Zhou J. Antitumor glycocyclohexapeptide from Rubia yunnanensis [J]. Acta Bot Yunnan, 1993, 15: 399-402.
60. Shen XY, Wu HM, He M, et al. 2D NMR investigation of glycocyclohexapeptide [J]. Acta Chim Sin, 1996, 54: 1194-1199.
61. Takeya K, Yamamiya T, Morita H, et al. Two antitumour bicyclic hexapeptides from Rubia cordifolia [J]. Phytochemistry, 1993, 33: 613-615.
62. Fan JT, Su J, Peng YM, et al. Rubiyunnanins C-H, cytotoxic cyclic hexapeptides from Rubia yunnanensis inhibiting nitric oxide production and NF-κ activation [J]. Bioorg Med Chem, 2010, 18: 8226-8234.
63. Hitotsuyanagi Y, Aihara T, Takeya K. RA-dimer A, a novel dimeric antitumor bicyclic hexapeptide from Rubia cordifolia L [J]. Tetrahedron Lett, 2000, 41: 6127-6130. (Pubitemid 30620159)
64. Fan JT, Chen YS, Xu WY, et al. Rubiyunnanins A and B, two novel cyclic hexapeptides from Rubia yunnanensis [J]. Tetrahedron Lett, 2010, 51: 6810-6813.
65. Morita H, Yamamiya T, Takeya K, et al. Conformational recognition of RA-XII by 80S ribosomes - a differential line broadening study in 1H NMR spectroscopy [J]. Chem Pharm Bull, 1993, 41: 781-783. (Pubitemid 23166161)
66. Yue GGL, Fan JT, Lee JKM, et al. Cyclopeptide RA-V inhibits angiogenesis by downregulating extracellular signal-regulated kinase 1/2 phosphorylation in HUVEC and HMEC-1 endothelial cells [J]. Br J Pharmacol, 2011, 164: 1883-1898.
67. Koizumi T, Abe M, Yamakuni T, et al. Metronomic scheduling of a cyclic hexapeptide RA-VII for anti-angiogenesis, tumor vessel maturation and anti-tumor activity [J]. Cancer Sci, 2006, 97: 665-674. (Pubitemid 44056615)
68. Bates RB, Gin SL, Hassen MA, et al. Synthesis of cyclo-N-methyl-L-Tyr-N- methyl-L-Tyr-D-Ala-L-Ala-O, N-dimethyl-L-Tyr-L-Ala, a cyclic hexapeptide related to the antitumor agent deoxybouvardin [J]. Heterocycles, 1984, 22: 785-790.
69. st total synthesis of deoxybouvardin and RA-VII, novel antitumor hexapeptides [J]. J Org Chem, 1987, 52: 2957-2958.
70. Boger DL, Yohannes D. Total synthesis of deoxybouvardin and RA-VII - macrocyclization via an intramolecular ullmann reaction [J]. J Am Chem Soc, 1991, 113: 1427-1429.
71. Beugelmans R, Bigot A, Bois-Choussy M, et al. A new approach to the synthesis of piperazinomycin and bouvardin: facile access to cycloisodityrosine via an intramolecular SNAR reaction [J]. J Org Chem, 1996, 61: 771-774.
72. Yan H, Pan XL, Tan NH, et al. 2D- and 3D-QSAR studies on 54 anti-tumor Rubiaceae-type cyclopeptides [J]. Eur J Med Chem, 2009, 44: 3425-3432.
73. Kosemura S, Ogawa T, Totsuka K. Isolation and structure of asterin, a new halogenated cyclic penta-peptide from Aster tataricus [J]. Tetrahedron Lett, 1993, 34: 1291-1294.
74. Morita H, Nagashima S, Takeya K, et al. Astins A and B, antitumor cyclic pentapeptides from Aster tataricus [J]. Chem Pharm Bull, 1993, 41: 992-993. (Pubitemid 23240074)
75. Morita H, Nagashima S, Takeya K, et al. Cyclic peptides from higher plants. Part 21. Thionation of the antitumor cyclic pentapeptides, astins A, B and C, from Aster tataricus [J]. J Chem Soc, Perkin Trans, 1995, 1: 2327-2331.
76. Morita H, Nagashima S, Shirota O, et al. Two novel monochlorinated cyclic pentapeptides, astins D and E, from Aster tataricus [J]. Chem Lett, 1993, 41: 1877-1880.
77. Morita H, Nagashima S, Takeya K, et al. Cyclic peptides from higher plants. Part 8. Three novel cyclic pentapeptides, astins F, G and H from Aster tataricus [J]. Heterocycles, 1994, 38: 2247-2252.
78. Morita H, Nagashima S, Takeya K, et al. Cyclic peptides from higher plants. II. A novel cyclic pentapeptdie with a β-hydroxy-y-chloroproline from Aster tataricus [J]. Chem Lett, 1994, 42: 2009-2010.
79. Cheng DL, Shao Y, Hartman R, et al. Oligopeptides from Aster tataricus [J]. Phytochemistry, 1994, 36: 945-948. (Pubitemid 2107454)
80. Cheng DL, Shao Y, Hartmann R, et al. New pentapeptides from Aster tataricus [J]. Phytochemistry, 1996, 41: 225-227.
81. Wang ZT, Lu YH, Ye WC, et al. A dipeptide isolated from Aster tataricus L.f [J]. J Chin Pharm Sci, 1999, 8: 171-172.
82. Shen Y, Luo Q, Xu HM, et al. Mitochondria-dependent apoptosis of activated T lymphocytes induced by astin C, a plant cyclopeptide, for preventing murine experimental colitis [J]. Biochem Pharmacol, 2011, 82: 260-268.